-
Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development
Latest News
-
Dimebon: disappointing in Alzheimer’s but might work in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Is Huntington’s disease twice as common as we thought?
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
-
Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Alnylam Pharmaceuticals
Expected:
2026
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Novartis/PTC Therapeutics
Expected:
Not disclosed
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Skyhawk Therapeutics
Expected:
Not disclosed